Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Total Stockholder's Equity	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Treasury Stock	Deferred Compensation	Noncontrolling Interests	Total
Beginning Balance at Oct. 31, 2022	$ 684,392	$ 41	$ 2,094,076	$ (1,407,973)	$ (1,752)	$ (855)	$ 855	$ 7,105	$ 691,497
Beginning Balance at (in shares) at Oct. 31, 2022		405,562,988
Common stock issued, non-employee compensation	68		68						68
Common stock issued, non-employee compensation (in shares)		21,106
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards	(314)		(314)						(314)
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)		169,065
Share based compensation	2,637		2,637						2,637
Preferred dividends - Series B	(800)		(800)						(800)
Effect of foreign currency translation	447				447				447
Adjustment for deferred compensation						(68)	68
Adjustment for deferred compensation (in shares)		(21,106)
Reclassification of redeemable non-controlling interest								3,030	3,030
Distribution to noncontrolling interest								(106)	(106)
Net Loss	(18,622)			(18,622)				(2,464)	(21,086)
Ending Balance at Jan. 31, 2023	667,808	$ 41	2,095,667	(1,426,595)	(1,305)	(923)	923	7,565	675,373
Ending Balance at (in shares) at Jan. 31, 2023		405,732,053
Beginning Balance at Oct. 31, 2022	684,392	$ 41	2,094,076	(1,407,973)	(1,752)	(855)	855	7,105	691,497
Beginning Balance at (in shares) at Oct. 31, 2022		405,562,988
Effect of foreign currency translation									296
Net loss attributable to noncontrolling interests									2,072
Net Loss									(54,997)
Ending Balance at Apr. 30, 2023	638,411	$ 41	2,100,724	(1,460,898)	(1,456)	(923)	923	7,814	646,225
Ending Balance at (in shares) at Apr. 30, 2023		406,738,713
Beginning Balance at Jan. 31, 2023	667,808	$ 41	2,095,667	(1,426,595)	(1,305)	(923)	923	7,565	675,373
Beginning Balance at (in shares) at Jan. 31, 2023		405,732,053
Sale of common stock, net of fees	2,663		2,663						2,663
Sale of common stock, net of fees (in shares)		949,438
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)		57,222
Share based compensation	3,194		3,194						3,194
Preferred dividends - Series B	(800)		(800)						(800)
Effect of foreign currency translation	(151)				(151)				(151)
Distribution to noncontrolling interest								(143)	(143)
Net loss attributable to noncontrolling interests									(392)
Net Loss	(34,303)			(34,303)				392	(33,911)
Ending Balance at Apr. 30, 2023	638,411	$ 41	2,100,724	(1,460,898)	(1,456)	(923)	923	7,814	646,225
Ending Balance at (in shares) at Apr. 30, 2023		406,738,713
Beginning Balance at Oct. 31, 2023	682,493	$ 45	2,199,661	(1,515,541)	(1,672)	(1,078)	1,078	17,955	$ 700,448
Beginning Balance at (in shares) at Oct. 31, 2023		450,626,862							450,626,862
Common stock issued, non-employee compensation	51		51						$ 51
Common stock issued, non-employee compensation (in shares)		44,398
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards	(926)		(926)						(926)
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)		1,235,192
Share based compensation	2,876		2,876						2,876
Preferred dividends - Series B	(800)		(800)						(800)
Effect of foreign currency translation	33				33				33
Adjustment for deferred compensation						(51)	51
Adjustment for deferred compensation (in shares)		(44,398)
Contributions received from sale of noncontrolling interest								25,122	25,122
Distribution to noncontrolling interest								(236)	(236)
Net Loss	(19,793)			(19,793)				(24,606)	(44,399)
Ending Balance at Jan. 31, 2024	663,934	$ 45	2,200,862	(1,535,334)	(1,639)	(1,129)	1,129	18,235	682,169
Ending Balance at (in shares) at Jan. 31, 2024		451,862,054
Beginning Balance at Oct. 31, 2023	682,493	$ 45	2,199,661	(1,515,541)	(1,672)	(1,078)	1,078	17,955	$ 700,448
Beginning Balance at (in shares) at Oct. 31, 2023		450,626,862							450,626,862
Effect of foreign currency translation									$ (45)
Net loss attributable to noncontrolling interests									30,122
Net Loss									(82,055)
Ending Balance at Apr. 30, 2024	639,806	$ 46	2,208,951	(1,567,474)	(1,717)	(1,164)	1,164	12,294	$ 652,100
Ending Balance at (in shares) at Apr. 30, 2024		458,406,776							458,406,776
Beginning Balance at Jan. 31, 2024	663,934	$ 45	2,200,862	(1,535,334)	(1,639)	(1,129)	1,129	18,235	$ 682,169
Beginning Balance at (in shares) at Jan. 31, 2024		451,862,054
Sale of common stock, net of fees	5,893	$ 1	5,892						5,893
Sale of common stock, net of fees (in shares)		6,463,716
Common stock issued, non-employee compensation	47		47						47
Common stock issued, non-employee compensation (in shares)		46,357
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards	(52)		(52)						(52)
Stock issued under benefit plans, net of taxes paid upon vesting of restricted stock awards (in shares)		68,597
Share based compensation	3,002		3,002						3,002
Preferred dividends - Series B	(800)		(800)						(800)
Effect of foreign currency translation	(78)				(78)				(78)
Adjustment for deferred compensation						(35)	35
Adjustment for deferred compensation (in shares)		(33,948)
Distribution to noncontrolling interest								(425)	(425)
Net loss attributable to noncontrolling interests									5,516
Net Loss	(32,140)			(32,140)				(5,516)	(37,656)
Ending Balance at Apr. 30, 2024	$ 639,806	$ 46	$ 2,208,951	$ (1,567,474)	$ (1,717)	$ (1,164)	$ 1,164	$ 12,294	$ 652,100
Ending Balance at (in shares) at Apr. 30, 2024		458,406,776							458,406,776